Cleerly to Debut Cleerly PREVIEW and Showcase New AI-QCT Research at ACC.26
New Product Enhancement and Four Scientific Presentations to Highlight Cleerly's Presence at the 75th Annual Scientific Session & Expo of the...
Cleerly AI-QCT Demonstrates High Agreement With Invasive IVUS in INVICTUS Registry
Multicenter INVICTUS Registry Demonstrates Strong Correlation Between Noninvasive AI-QCT and Invasive IVUS for Coronary Plaque Quantification
Aetna Approves Coverage for Cleerly's AI Cardiovascular Imaging Analysis
Major Insurer Joins UnitedHealthcare, Cigna, and Humana in Covering Cleerly's AI-QCT Technology as Industry Momentum Builds with 86+ Million Lives...
CVCT 2025: Cleerly Late-Breaking Science Identifies Thresholds of High Plaque Burden in Non-Obstructive CAD that May Carry Greater Risk Than Obstructive Disease
Sixth late-breaking presentation from CONFIRM2 Registry demonstrates 12-fold risk gradient based on total plaque burden
